Comparison of Outcomes After Primary Versus Salvage Osteochondral Allograft Transplantation for Femoral Condyle Osteochondritis Dissecans Lesions.

"One or more of the authors has declared the following potential conflict of interest or source of funding: C.N. has received financial or material support from AO Foundation and Arthroscopy; education payments from Arthrex and Elite Orthopedics; consulting fees from Arthrex and Guidepoint Consulting; nonconsulting fees from Vericel, Arthrex, and Stryker; royalties from Arthroscopy; and hospitality payments from Synthes GmbH. J.P.S. has received research support from Arthrex; financial or material support from Thieme; education payments from Elite Orthopedics; consulting fees from Medical Device Business Services, DePuy, Orthopedic Designs North America, Smith & Nephew, and Arthrex; nonconsulting fees from Synthes GmbH and Medical Device Business Services; and royalties from Thieme. R.M. has received research support from Cartiheal, Moximed, and Novocart. M.K. has received education payments from Elite Orthopedics and Arthrex; nonconsulting fees from Synthes GmbH; and honoraria from Synthes GmbH. J.L.C. has received research support from AO Trauma, Arthrex, Collagen Matrix, DePuy, Orthopaedic Trauma Association, Purina, Regenosine, and SITES Medical; financial or material support from Thieme; consulting fees from Arthrex and Trupanion; royalties from Arthrex, MTF Biologics, and Thieme; and is a board or committee member for MTF Biologics. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto."

"One or more of the authors has declared the following potential conflict of interest or source of funding: C.N. has received financial or material support from AO Foundation and Arthroscopy; education payments from Arthrex and Elite Orthopedics; consulting fees from Arthrex and Guidepoint Consulting; nonconsulting fees from Vericel, Arthrex, and Stryker; royalties from Arthroscopy; and hospitality payments from Synthes GmbH. J.P.S. has received research support from Arthrex; financial or material support from Thieme; education payments from Elite Orthopedics; consulting fees from Medical Device Business Services, DePuy, Orthopedic Designs North America, Smith & Nephew, and Arthrex; nonconsulting fees from Synthes GmbH and Medical Device Business Services; and royalties from Thieme. R.M. has received research support from Cartiheal, Moximed, and Novocart. M.K. has received education payments from Elite Orthopedics and Arthrex; nonconsulting fees from Synthes GmbH; and honoraria from Synthes GmbH. J.L.C. has received research support from AO Trauma, Arthrex, Collagen Matrix, DePuy, Orthopaedic Trauma Association, Purina, Regenosine, and SITES Medical; financial or material support from Thieme; consulting fees from Arthrex and Trupanion; royalties from Arthrex, MTF Biologics, and Thieme; and is a board or committee member for MTF Biologics. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto."